Adtran Networks SE reports second quarter 2023 results
Adtran Networks SE (ISIN: DE0005103006, FSE: ADV), a leading provider of open networking solutions for the delivery of cloud and mobile services, reported financial results for the second quarter 2023 ended on June 30, 2023. The results have been prepared in accordance with International Financial Reporting Standards (IFRS).
Q2 2023 financial summary1
|
(in thousands of EUR) |
Q2 |
Q2 |
Change |
Q1 |
Change |
|
|
|
2023 |
2022 |
|
2023 |
|
|
|
|
||||||
|
Revenues |
170,188 |
166,320 |
2.3% |
179,358 |
-5.1% |
|
|
Pro forma gross profit |
60,232 |
54,336 |
10.9% |
58,371 |
3.2% |
|
|
in % of revenues |
35.4% |
32.7% |
2.7pp |
32.5% |
2.8pp |
|
|
Pro forma EBIT |
12,092 |
6,435 |
87.9% |
9,730 |
24.3% |
|
|
in % of revenues |
7.1% |
3.9% |
3.2pp |
5.4% |
1.7pp |
|
|
Operating income2 |
8,033 |
4,655 |
72.6% |
6,227 |
29.0% |
|
|
Net income |
3,288 |
7,291 |
-54.9% |
3,627 |
-9.3% |
|
|
|
||||||
|
(in thousands of EUR) |
Jun. 30 2023 |
Jun. 30 2022 |
Change |
Mar. 31 2023 |
Change |
|
|
Cash and cash equivalents |
48,595 |
63,187 |
-23,1% |
67,241 |
-27.7% |
|
|
Net cash (+) / Net debt (-)3 |
-33,457 |
-946 |
-3,436.7% |
-24,296 |
-37.7% |
|
|
1 Potential difference due to rounding |
|
2 Q2 2023 including EUR 1.7 million, Q1 2023 including EUR 1.6 million and Q2 2022 including EUR 0.4 million extraordinary expenses |
|
3 Q2 2023 including EUR 53.0 million and Q1 2023 Including EUR 62.0 million financial liabilities to Adtran Holdings, Inc. |
Q2 2023 IFRS financial results
Revenue in Q2 2023 was down 5.1% to EUR 170.2 million from EUR 179.4 million in Q1 2023 and was up 2.3% compared to EUR 166.3 million in Q2 2022. The US Dollar depreciation negatively impacted both year-over-year and quarter-over-quarter revenue. The decrease compared to the previous quarter was mainly due to a softening in demand compared to a strong Q1 2023.
Pro forma gross profit in Q2 2023 was up 3.2% to EUR 60.2 million (35.4% of revenues) from EUR 58.4 million (32.5% of revenues) in Q1 2023 and increased by 10.9% from EUR 54.3 million (32.7% of revenues) in the year-ago quarter. The margin increase is due to lower procurement costs related to the recovery of supply bottlenecks and the US Dollar depreciation.
Pro forma EBIT in Q2 2023 was EUR 12.1 million (7.1% of revenues), up 24.3% from EUR 9.7 million (5.4% of revenues) in Q1 2023. Compared to the year-ago quarter, pro forma operating income increased by 87.9% from EUR 6.4 million (3.9% of revenues). The increase in pro forma EBIT is mainly due to the improvement in gross margin.
Operating income increased by 29.0% from EUR 6.2 million in Q1 2023 to EUR 8.0 million in Q2 2023 and increased by 72.6% compared to EUR 4.7 million in Q2 2022.
Net income was EUR 3.3 million in Q2 2023, down 9.3% compared to EUR 3.6 million in Q1 2023 and down 54.9% compared to EUR 7.3 million in Q2 2022. The decrease in net income was due to higher tax charges in Q2 2023.
The company’s cash and cash equivalents decreased by EUR 18.6 million to EUR 48.6 million compared to EUR 67.2 million at the end of Q1 2023 and decreased by EUR 14.6m million compared to EUR 63.2 million in Q2 2022.
The company’s net debt increased by EUR 9.2 million from EUR 24.3 million in Q1 2023 to EUR 33.5 million in Q2 2023 and increased by EUR 32.5 million compared to EUR 0.9 million in Q2 2022.
Management commentary
“Our Q2 2023 results were in line with our expectations. We anticipate the second half of 2023 will continue to present challenges due to customers optimizing inventory and the macro-economic environment,” said Tom Stanton, CEO of Adtran Networks SE. “Nevertheless, we continue to believe that we are in the early stage of an unprecedented investment cycle and Adtran Networks is well positioned to be one of the largest beneficiaries.”
The company will publish its financial results for Q3 2023 on November 7, 2023.
The complete half-year report 2023 (January – June) is available as a PDF: https://www.adva.com/en/about-us/investors/financial-results/financial-statements
Forward-looking statements
The economic projections and forward-looking statements contained in this document relate to future facts. Such projections and forward-looking statements are subject to risks that cannot be foreseen and that are beyond the control of Adtran Networks. Adtran Networks is therefore not in a position to make any representation as to the accuracy of economic projections and forward-looking statements or their impact on the financial situation of Adtran Networks or the market in the shares of Adtran Networks.
Use of pro forma financial information
Adtran Networks SE provides consolidated pro forma financial results in this press release solely as supplemental financial information to help investors and the financial community make meaningful comparisons of Adtran Networks operating results from one financial period to another. Adtran Networks believes that these pro forma consolidated financial results are helpful because they exclude non-cash charges related to the stock option programs and amortization and impairment of goodwill and acquisition-related intangible assets, which are not reflective of the company’s operating results for the period presented. Additionally, non-recurring expenses relating to M&A restructuring measures are not included. This pro forma information is not prepared in accordance with IFRS and should not be considered a substitute for the historical information presented in accordance with IFRS.
About Adtran Networks SE
Adtran Networks SE is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
Published by
Adtran Networks SE, Munich, Germany
www.adva.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230807817189/en/
Contact information
For press
Gareth Spence
+44 1904 699 358
public-relations@adva.com
For investors
Steven Williams
+49 89 890 665 918
investor-relations@adva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Making Science Unveils ‘AWAKE’: The AI Venture Studio Industrialising Startup Creation and AI-First Innovative Solutions23.12.2025 21:51:00 EET | Press release
Making Science, the global digital acceleration consultancy, today announced the launch of AWAKE Venture Studio. This "AI-first" model represents a new era in systematic innovation, designed to identify, prototype, and scale both internal proprietary solutions and independent AI-native startups with global reach. The launch of AWAKE is motivated by the significant efficiency gains of orders of magnitude that Making Science has already achieved through the internal integration of AI. By applying these methods, the firm has achieved a 2x acceleration in tech feature development reducing time in the deployment of AI Agents. This model has already proven its commercial and innovative power through the acceleration of startups like ad-machina, which has multiplied its value by 10 since joining the Making Science ecosystem. These proven benchmarks serve as the technical foundation for AWAKE’s two interconnected engines, which formalise this efficiency into a repeatable manufacturing process
FDA Clears First Extended Depth of Focus Contact Lens for Presbyopia23.12.2025 19:07:00 EET | Press release
The Cataltheia Group and its U.S. subsidiary, Bruno Vision Care LLC, a leader in eye health innovation, today announced that the U.S. Food and Drug Administration (FDA) has cleared the first and only Daily Disposable Soft (Hydrophilic) Contact Lens for Presbyopia utilizing patented Extended Depth of Focus (EDOF) optical design technology, enabling commercial distribution in the United States. Deseyne® delivers smooth, continuous focus across near, intermediate, and distance vision, providing clear, natural vision without compromise. This performance is enabled by Cataltheia’s patented hyper-refractive central zone, engineered to precisely redirect light in a controlled manner. The result is a clear clinical advantage over the only other available contact lens option for presbyopia, multifocal lenses, which rely on multiple optical zones and often require prolonged visual and cognitive adaptation. “We are proud to offer the first contact lens solution for the world’s aging population th
Aramco Awards SLB Long-Term Contract to Support Kingdom’s Unconventional Gas Production Growth23.12.2025 15:58:00 EET | Press release
Global technology company SLB (NYSE: SLB) has been awarded a five-year contract by Aramco to provide stimulation services for its unconventional gas fields. This award is part of a broader multi-billion contract, supporting one of the largest unconventional gas development programs globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251223074948/en/ The contract encompasses advanced stimulation, well intervention, frac automation, and digital solutions, which are important to unlocking the potential of Saudi Arabia’s unconventional gas resources. The contract encompasses advanced stimulation, well intervention, frac automation, and digital solutions, which are important to unlocking the potential of Saudi Arabia’s unconventional gas resources — a cornerstone of the Kingdom’s strategy to diversify its energy portfolio and support the global energy transition. “This agreement is an important step forward in Aramco’s effor
Tabelog, Japan's Largest (*1) Restaurant Search and Reservation Service, Launches Multilingual App for International Visitors23.12.2025 15:00:00 EET | Press release
Tabelog (https://tabelog.com/en/), Japan's largest restaurant search and reservation service operated by Kakaku.com, Inc., launched its multilingual smartphone application (iOS/Android) for international travelers on Monday, November 17, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251221963753/en/ The Tabelog Multilingual App for International Travelers — Japan's Largest Restaurant Search and Reservation Service With approximately 100 million monthly users(*3), Tabelog is Japan's premier service widely used by Japanese locals for daily restaurant discovery. Its database is unrivaled domestically, featuring information on approximately 890,000 establishments nationwide and over 85 million reviews and photos(*4). Unlike global map services or travel sites, Tabelog is built on "authentic ratings and reviews from local Japanese users," enabling travelers to discover truly exceptional restaurants beloved by locals — not
BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference23.12.2025 13:01:00 EET | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, with a presentation at 7:30 am PST. Live webcasts of these events can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com, https://hkexir.beonemedicines.com, https://sseir.beonemedicines.com. Archived replays will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company based in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of nearly 12,000 colleagues spanning six continents, the Company is committed to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
